Happy Holidays and New year from the EMDB! Please be advised that the EMDB team will be operating at reduced capacity between December 15th - January 12th. With this in mind we would ask that you be prepared for longer reply times through both our helpdesk system and the OneDep deposition system. well done on a productive 2025, wishing you all the best and we will see you in 2026!
EMD-26064
SARS-CoV-2 S + Fabs 5317-4 and 5217-10
EMD-26064
Single-particle8.64 Å
Deposition: 26/01/2022Map released: 09/03/2022
Last modified: 17/01/2024
Sample Organism:
Severe acute respiratory syndrome coronavirus 2
Sample: Complex of SARS-CoV-2 S-ECD with Fabs 5317-4 and 5317-10
Deposition Authors: Johnson NV
,
McLellan JS
Sample: Complex of SARS-CoV-2 S-ECD with Fabs 5317-4 and 5317-10
Deposition Authors: Johnson NV
,
McLellan JS
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking.
Shiakolas AR ,
Kramer KJ ,
Johnson NV ,
Wall SC,
Suryadevara N ,
Wrapp D ,
Periasamy S ,
Pilewski KA ,
Raju N,
Nargi R,
Sutton RE,
Walker LM,
Setliff I ,
Crowe Jr JE ,
Bukreyev A ,
Carnahan RH ,
McLellan JS ,
Georgiev IS
(2022) Nat Biotechnol , 40 , 1270 - 1275
,
Kramer KJ ,
Johnson NV ,
Wall SC,
Suryadevara N ,
Wrapp D ,
Periasamy S ,
Pilewski KA ,
Raju N,
Nargi R,
Sutton RE,
Walker LM,
Setliff I ,
Crowe Jr JE ,
Bukreyev A ,
Carnahan RH ,
McLellan JS ,
Georgiev IS
(2022) Nat Biotechnol , 40 , 1270 - 1275
Grant Support: